From the Wires
Levi & Korsinsky Notifies Investors With Losses on Their Investment in Hemispherx Biopharma, Inc. of Class Action Lawsuit and the Deadline of March 5, 2013 to Seek a Lead Plaintiff Position
By: Marketwired .
Feb. 6, 2013 06:10 PM
NEW YORK, NY -- (Marketwire) -- 02/06/13 -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of investors who acquired Hemispherx Biopharma, Inc. ("Hemispherx" or "the Company") (NYSE MKT: HEB) stock between March 19, 2012 and December 17, 2012.
For more information, click here: http://zlk.9nl.com/hemispherix-biopharma-heb/.
The Complaint asserts violations of the federal securities laws against Hemispherx and its officers and directors for issuing false and misleading information about its lead drug candidate Ampligen. Specifically, that Hemispherx misstated the safety and efficacy of Ampligen, and touted purportedly positive results from Ampligen's clinical trials. On December 18, 2012, the FDA published a staff report concluding that the Company's studies were "ill-defined and invalid" with signals of efficacy that were inconsistent between clinical trials, and based on the limited quality of the data, "it is difficult to draw conclusions regarding potential safety signals," but the "review identified nine potential safety concerns associated with Ampligen." The Complaint alleges that as a result of this adverse information, Hemispherx stock price dropped from $0.64 to $0.37.
If you suffered a loss in Hemispherx you have until February 22, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (877) 363-5972, or visit http://zlk.9nl.com/hemispherix-biopharma-heb/.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
SOA World Latest Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week